Antibody


Last updated: 2021 Oct 31
Total hit(s): 45
Select item(s)
Key Findings
Comments
(You can add your comments too!)
Original Article
(hover to see details)
In convalescent patients, more than 80% of the anti-spike IgG antibody response is directed against epitopes outside the receptor binding domain (RBD). In one patient, antibodies were aimed at the amino (N)-terminal domain (NTD) that proved protective against a deadly viral attack. In a high viral load test, a cocktail of the top non-RBD plasma mAbs CM29CM31 (>85% of the IgG plasma lineages to S-ECD) provided the most effective protection and lung viral titers below the limit of detection (LOD) (10^4 PFU).
33947773
(Science)
PMID
33947773
Date of Publishing: 2021 May 4
Title Prevalent, protective, and convergent IgG recognition of SARS-CoV-2 non-RBD spike epitopes
Author(s) nameVoss WN, Hou YJ et al.
Journal Science
Impact factor
20.57
Citation count: 58
Date of Entry 2021 Oct 31


3 Monoclonal antibodies (mAb#1, mAb#2, mAb#3) were raised against the NRP1 b1b2 ectodomain to establish functional relevance of S1 CendR-NRP1 interaction. NRP1 enhances the infectivity of SARS-CoV-2 by S1 interaction and also a CendR independent mechanism. mAb1 and mAb3 can control SARS-CoV-2 infections to a large extent. Small molecule EG00229 inhibits the direct binding of b1 with S1 CendR peptide
33082294
(Science)
PMID
33082294
Date of Publishing: 2020 Nov 13
Title Neuropilin-1 is a host factor for SARS-CoV-2 infection
Author(s) nameDaly JL, Simonetti B et al.
Journal Science
Impact factor
20.57
Citation count: 373
Date of Entry 2021 Aug 2


Neutralizing antibodies coupled on the photothermal nanoparticle helps in inactivation of virus by preventing the entry of virus into ACE-2 expressing host cell. Toxicity was not observed.
33269351
(bioRxiv)
PMID
33269351
Date of Publishing: 2020 Nov 30
Title A Neutralizing Antibody-Conjugated Photothermal Nanoparticle Captures and Inactivates SARS-CoV-2
Author(s) nameCai X, Prominski A et al.
Journal bioRxiv
Impact factor
N/A
Citation count: 9


The neutralizing potential efficiency of anti-Spike-S1 IgYs (chicken egg yolk antibodies) that blocks the binding of various variants of SARS-CoV-2 spike protein to ACE-2 receptor was researched.
33191178
(Int Immunopharmacol)
PMID
33191178
Date of Publishing: 2020 Nov 3
Title Chicken Egg Yolk Antibodies (IgYs) block the binding of multiple SARS-CoV-2 spike protein variants to human ACE2
Author(s) nameWei S, Duan S et al.
Journal Int Immunopharmacol
Impact factor
3.38
Citation count: 3


REGN-COV2 antibodies are efficacious when used prophylactically or therapeutically. This mAB cocktail could reduce the viral load and also decrease virus-induced pathological sequelae in rhesus macaque and limit weight loss in hamsters.
33037066
(Science)
PMID
33037066
Date of Publishing: 2020 Nov 27
Title REGN-COV2 antibodies prevent and treat SARS-CoV-2 infection in rhesus macaques and hamsters.
Author(s) nameBaum A, Ajithdoss D et al.
Journal Science
Impact factor
20.57
Citation count: 202


4A8 monoclonal antibody shows a high affinity to bind to the polybasic insert at the furin-like cleavage site. 1.) in silico screening of SARS-CoV-2 neutralizing mAbs: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7709177/table/T1/ and 2.) Supplementary data: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7709177/#SD1
33269352
(bioRxiv)
PMID
33269352
Date of Publishing: 2020 Nov 24
Title A monoclonal antibody against staphylococcal enterotoxin B superantigen inhibits SARS-CoV-2 entry in vitro
Author(s) nameCheng MH, Porritt RA et al.
Journal bioRxiv
Impact factor
N/A
Citation count: 3


6D3 monoclonal antibody can block the SARS-CoV infection by inhibiting the access of host cell proteases, TMPRSS2 or furin. Figures: 1.)Binding poses: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7709177/figure/F2/ 2.) 4A8 binding characteristics examination: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7709177/figure/F3/ 3.) 6D3 inhibiting SARS-CoV-2 data: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7709177/figure/F5/ 4.) Polyacidic residues in the CDR2 of 6D3 and 4A8 heavy chains: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7709177/figure/F6/
33269352
(bioRxiv)
PMID
33269352
Date of Publishing: 2020 Nov 24
Title A monoclonal antibody against staphylococcal enterotoxin B superantigen inhibits SARS-CoV-2 entry in vitro
Author(s) nameCheng MH, Porritt RA et al.
Journal bioRxiv
Impact factor
N/A
Citation count: 3


A monoclonal Antibody (2B04) potently inhibited SARS-CoV-2 infection with an IC50 of 3.007 ng/mL.
33035201
(JCI Insight)
PMID
33035201
Date of Publishing: 2020 Nov 19
Title Neutralizing antibody against SARS-CoV-2 spike in COVID-19 patients, health care workers and convalescent plasma donors.
Author(s) nameZeng C, Evans JP et al.
Journal JCI Insight
Impact factor
6.014
Citation count: 29


Of the 35 monoclonal anti-bodies 'isolate', mAb 4A8 displayed high neutralizing activity against both the authentic and pseudotyped SARS-CoV2.
32571838
(Science)
PMID
32571838
Date of Publishing: 2020 Aug 7
Title A neutralizing human antibody binds to the N-terminal domain of the Spike protein of SARS-CoV-2
Author(s) nameChi X, Yan R et al.
Journal Science
Impact factor
20.57
Citation count: 502


Of the 35 monoclonal anti-bodies isolate, mAb IM-ID2 displayed high neutralizing activity against live SARS-CoV2.
32571838
(Science)
PMID
32571838
Date of Publishing: 2020 Aug 7
Title A neutralizing human antibody binds to the N-terminal domain of the Spike protein of SARS-CoV-3
Author(s) nameChi X, Yan R et al.
Journal Science
Impact factor
20.57
Citation count: 502


Of the 35 monoclonal anti-bodies 'isolate', mAb 0304-3H3 displayed high neutralizing activity against live SARS-CoV2.
32571838
(Science)
PMID
32571838
Date of Publishing: 2020 Aug 7
Title A neutralizing human antibody binds to the N-terminal domain of the Spike protein of SARS-CoV-4
Author(s) nameChi X, Yan R et al.
Journal Science
Impact factor
20.57
Citation count: 502


Monoclonal antibody MD63 did not show neutralizing activity in the plaque reduction neutralization test (PRNT) using VeroE6 cells infected with the pathogenic SARS-CoV-2.
32855401
(Nat Commun)
PMID
32855401
Date of Publishing: 2020 Aug 27
Title A panel of human neutralizing mAbs targeting SARS-CoV-2 spike at multiple epitopes
Author(s) nameNoy-Porat T, Makdasi E et al.
Journal Nat Commun
Impact factor
11.8
Citation count: 67


Monoclonal antibody MD65 showed neutralizing activity in the plaque reduction neutralization test (PRNT) using VeroE6 cells infected with the pathogenic SARS-CoV-2. Monoclonal antibody MD65 inhibits the binding of RBD to human ACE2
32855401
(Nat Commun)
PMID
32855401
Date of Publishing: 2020 Aug 27
Title A panel of human neutralizing mAbs targeting SARS-CoV-2 spike at multiple epitopes
Author(s) nameNoy-Porat T, Makdasi E et al.
Journal Nat Commun
Impact factor
11.8
Citation count: 67


Monoclonal antibody MD45 showed neutralizing activity in the plaque reduction neutralization test (PRNT) using VeroE6 cells infected with the pathogenic SARS-CoV-2.
32855401
(Nat Commun)
PMID
32855401
Date of Publishing: 2020 Aug 27
Title A panel of human neutralizing mAbs targeting SARS-CoV-2 spike at multiple epitopes
Author(s) nameNoy-Porat T, Makdasi E et al.
Journal Nat Commun
Impact factor
11.8
Citation count: 67


Monoclonal antibody MD67 showed neutralizing activity in the plaque reduction neutralization test (PRNT) using VeroE6 cells infected with the pathogenic SARS-CoV-2.
32855401
(Nat Commun)
PMID
32855401
Date of Publishing: 2020 Aug 27
Title A panel of human neutralizing mAbs targeting SARS-CoV-2 spike at multiple epitopes
Author(s) nameNoy-Porat T, Makdasi E et al.
Journal Nat Commun
Impact factor
11.8
Citation count: 67


Monoclonal antibody MD62 showed neutralizing activity in the plaque reduction neutralization test (PRNT) using VeroE6 cells infected with the pathogenic SARS-CoV-2. Monoclonal antibody MD62 inhibits the binding of RBD to human ACE2
32855401
(Nat Commun)
PMID
32855401
Date of Publishing: 2020 Aug 27
Title A panel of human neutralizing mAbs targeting SARS-CoV-2 spike at multiple epitopes
Author(s) nameNoy-Porat T, Makdasi E et al.
Journal Nat Commun
Impact factor
11.8
Citation count: 67


Monoclonal antibody MD29 showed neutralizing activity in the plaque reduction neutralization test (PRNT) using VeroE6 cells infected with the pathogenic SARS-CoV-2. Monoclonal antibody MD29 which recognizes the same epitope as antibody CR3022 does not inhibit the binding of RBD to human ACE2
32855401
(Nat Commun)
PMID
32855401
Date of Publishing: 2020 Aug 27
Title A panel of human neutralizing mAbs targeting SARS-CoV-2 spike at multiple epitopes
Author(s) nameNoy-Porat T, Makdasi E et al.
Journal Nat Commun
Impact factor
11.8
Citation count: 67


Monoclonal antibody MD17 showed a poor neutralizing activity (NT50) in the plaque reduction neutralization test (PRNT) using VeroE6 cells infected with the pathogenic SARS-CoV-2.
32855401
(Nat Commun)
PMID
32855401
Date of Publishing: 2020 Aug 27
Title A panel of human neutralizing mAbs targeting SARS-CoV-2 spike at multiple epitopes
Author(s) nameNoy-Porat T, Makdasi E et al.
Journal Nat Commun
Impact factor
11.8
Citation count: 67


A monoclonal antibody (CC12.1) neutralized SARS-CoV-2 in vitro and provided full protection against SARS-CoV-2 infection in Syrian hamsters at a serum concentration of ~22 μg/ml.
32540903
(Science)
PMID
32540903
Date of Publishing: 2020 Aug 21
Title Isolation of potent SARS-CoV-2 neutralizing antibodies and protection from disease in a small animal model
Author(s) nameRogers TF, Zhao F et al.
Journal Science
Impact factor
20.57
Citation count: 589


A monoclonal antibody (CC12.23) neutralized SARS-CoV-2 in vitro and did not protect against SARS-CoV-2 infection in Syrian hamsters at any concentration.
32540903
(Science)
PMID
32540903
Date of Publishing: 2020 Aug 21
Title Isolation of potent SARS-CoV-2 neutralizing antibodies and protection from disease in a small animal model
Author(s) nameRogers TF, Zhao F et al.
Journal Science
Impact factor
20.57
Citation count: 589


A monoclonal antibody (COV2-2196) protected mice and rhesus macaques from SARS-CoV-2 infection. A combination of this monoclonal antibody and COV2-2130 also protected mice from SARS-CoV-2 infection.
32668443
(Nature)
PMID
32668443
Date of Publishing: 2020 Aug
Title Potently neutralizing and protective human antibodies against SARS-CoV-2
Author(s) nameZost SJ, Gilchuk P et al.
Journal Nature
Impact factor
24.36
Citation count: 369


A monoclonal antibody (mAb) (COV2-2130) protected mice from SARS-CoV-2 infection. A combination of this mAb and COV2-2196 also protected mice from SARS-CoV-2 infection.
32668443
(Nature)
PMID
32668443
Date of Publishing: 2020 Aug
Title Potently neutralizing and protective human antibodies against SARS-CoV-2
Author(s) nameZost SJ, Gilchuk P et al.
Journal Nature
Impact factor
24.36
Citation count: 369


A monoclonal antibody (COV2-2381) protected rhesus macaques against SARS-CoV-2 infection.
32668443
(Nature)
PMID
32668443
Date of Publishing: 2020 Aug
Title Potently neutralizing and protective human antibodies against SARS-CoV-2
Author(s) nameZost SJ, Gilchuk P et al.
Journal Nature
Impact factor
24.36
Citation count: 369


The P2C-1F11 antibody was found to be the most potent in the neutralization of pseudoviruses bearing SARS-CoV-2 spike protein or live SARS-CoV-2.
32454513
(Nature)
PMID
32454513
Date of Publishing: 2020 Aug
Title Human neutralizing antibodies elicited by SARS-CoV-2 infection
Author(s) nameJu B, Zhang Q et al.
Journal Nature
Impact factor
24.36
Citation count: 721


The P2B-2F6 antibody was found to be the most potent in neutralization of pseudoviruses bearing SARS-CoV-2 spike protein or live SARS-CoV-2.
32454513
(Nature)
PMID
32454513
Date of Publishing: 2020 Aug
Title Human neutralizing antibodies elicited by SARS-CoV-2 infection
Author(s) nameJu B, Zhang Q et al.
Journal Nature
Impact factor
24.36
Citation count: 721